


**BAL PHARMA LIMITED**

Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099  
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31.03.2013

(Rs in Lakh)

Sr. No:	Particulars	Quarter Ended			Year Ended	
		31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012
		Unaudited	Unaudited	Unaudited	Audited	Audited
1	Net Sales/Income from operations (Net of Excise Duty)	4,155.63	3,446.57	3,841.80	14,430.36	13,648.98
	Other Operating Income	126.24	89.55	189.13	361.08	319.68
	<b>Net Income from Sales/Services</b>	<b>4,281.88</b>	<b>3,536.12</b>	<b>4,030.93</b>	<b>14,791.45</b>	<b>13,968.66</b>
2	Expenditure					
	a) Increase/decrease in stock in trade and WIP	100.48	151.85	317.38	244.71	120.28
	b) Consumption of Raw Materials/ Packing Material	2,118.81	1,500.15	1,673.63	7,209.61	7,184.63
	c) Purchase of Stock in Trade	121.64	152.78	154.19	440.16	375.24
	d) Employee Cost	588.24	599.47	492.42	2,357.48	2,115.41
	e) Depreciation and amortisation expenses	183.66	102.13	150.41	481.22	413.08
	f) Other Expenditure	775.82	701.57	836.63	2,817.61	2,692.76
	g) Total	<b>3,888.64</b>	<b>3,207.95</b>	<b>3,624.67</b>	<b>13,550.78</b>	<b>12,901.40</b>
3	Profit from Operations before other income, interest and Exceptional items(1-2)	<b>393.23</b>	<b>328.17</b>	<b>406.26</b>	<b>1,240.66</b>	<b>1,067.26</b>
4	Other Non-operating Income	36.19	6.60	(23.31)	65.93	107.81
5	Profit before Interest and Exceptional items (3+4)	<b>429.42</b>	<b>334.77</b>	<b>382.95</b>	<b>1,306.59</b>	<b>1,175.07</b>
6	Finance Costs	200.55	191.97	199.63	797.68	738.51
7	Profit after Interest but before Exceptional items	228.86	142.80	183.32	508.91	436.56
8	Exceptional items	-	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax ( 7-8)	228.86	142.80	183.32	508.91	436.56
10	Tax expenses	16.68	38.65	15.87	80.56	60.87
11	Net Profit /Loss from ordinary Activities after Tax	212.19	104.15	167.45	428.35	375.69
12	Extra ordinary items	-	-	-	-	-
13	Net Profit / Loss for the period	212.19	104.15	167.45	428.35	375.69
14	Paid-up Equity Share capital( face value of Rs 10 each )	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				2,948.22	2,602.41
16	<b>EPS ( in Rs. )</b>					
	Basic & Diluted	<b>2.01</b>	<b>0.99</b>	<b>1.58</b>	<b>4.05</b>	<b>3.57</b>
17	<b>Public shareholding</b>					
	- Number of Shares	5,142,086	5,142,086	5,132,086	5,142,086	5,132,086
	- Percentage of shareholding	48.63	48.63	48.54	48.63	48.53
18	<b>Promoters &amp; Promoter group Shareholding</b>					
	<b>a) Pledged / Encumbered</b>					
	- Number of Shares	-	-	-	-	-
	- Percentage of shareholding	-	-	-	-	-
	<b>b) Non-encumbered</b>					
	- Number of Shares	5,431,538	5,431,538	5,441,538	5,431,538	5,441,538
	- Percentage of shareholding	51.37	51.37	51.46	51.37	51.47

## Notes:

1 The statement of assets and liabilities as at 31.03.2013 are as follows;

Rs.in Lakh

Particulars	31.03.2013	31.03.2012
Share Capital	1,057.36	1,057.36
Reserves & Surplus	3,283.79	2,948.22
Money received against share warrant	120.68	-
	<b>4,461.83</b>	<b>4,005.58</b>
<b>Non Current Liabilities</b>		
Long-term borrowings	167.10	609.09
Deferred tax liabilities (Net)	823.72	741.77
Other long term liabilities	181.00	63.72
Long-term provisions	83.50	64.37
	<b>1,255.32</b>	<b>1,478.95</b>
<b>Current liabilities</b>		
Short- term borrowings	4,435.97	4,452.94
Trade payables	3,205.64	2,692.17
Other current liabilities	1,496.93	1,395.66
Short- term provisions	128.07	91.08
	<b>9,266.61</b>	<b>8,631.85</b>
<b>TOTAL</b>	<b>14,983.76</b>	<b>14,116.38</b>
<b>Non- current assets</b>		
Fixed Assets	5,270.31	5,330.99
Non- current investments	1.50	1.50
Long term loans and advances	383.46	318.26
Other non-current assets	7.10	17.22
	<b>5,662.37</b>	<b>5,667.97</b>
<b>Current assets</b>		
Inventories	3,368.70	3,365.96
Trade receivables	4,349.61	3,818.58
Cash and cash equivalents	472.84	302.67
Short-term loans and advances	1,105.01	931.34
Other current assets	25.23	29.86
	<b>9,321.39</b>	<b>8,448.41</b>
<b>TOTAL</b>	<b>14,983.76</b>	<b>14,116.38</b>

2 The above Audited financial results, as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 27.05.2013.

3 The net profit of previous financial year 31.03.2012 includes Rs.87.80 Lakhs from sale of fixed asset owned by the company.

4 The Board has recommended a dividend of Re.0.75 per equity share of Rs.10 each(i.e 7.5%), for the F.Y 2012.13.

5 Financials for the quarter ended on 31.03.2013 and 31.03.2012 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter.

6 During the financial year , the Company has successfully concluded the preferential allotment of 22,98,748 warrants with a conversion price of Rs.21/- per warrant,to the promoters and strategic investors.The warrants are outstanding for conversion.

7 Investor grievances: Outstanding at the beginning of the quarter : Nil , received during the quarter: 19,resolved during the quarter:19,pending at the end of the quarter: Nil.

8 As the Company deals with a single product i.e Pharmaceuticals, segment wise figures are not furnished.

9 The figures for the previous year have been regrouped/rearranged wherever required to confirm to the classification of the current year.

Bangalore  
27th May 2013

By order of the Board of Directors  
**For Bal Pharma limited**

**Shailesh Siroya**  
**Managing Director**



